Drug Discovery · Planegg-Martinsried, Germany · Founded 2012 · Privately Held (backing)
Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases. Tubulis is based in Planegg-Martinsried, Germany and was founded in 2012. It was valued at $5.8 billion at a merger or acquisition in Apr 2026, the last priced event on record. It has raised $618 million across 1 recorded round; the latest was a $361 million Series C in Oct 2025.
PMV mark · valuation
$5.8B
Oct 2026
Priced at
a merger or acquisition
Apr 2026
Total raised
$618.5M
Last round
Later Stage VC (Series C)
Oct 2025
No prints on record
No secondary trades in Tubulis shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Tubulis with a free account
·The complete investor list: 26 names
·Everyone on the team, board and advisors included
·Watch Tubulis: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Tubulis stock.
Tubulis Stock Price — Secondary Market Trades | Premier Alternatives
